Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus MICONAZOLE NITRATE COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus MICONAZOLE NITRATE COMBINATION PACK.
AMPHOTERICIN B vs MICONAZOLE NITRATE COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Miconazole nitrate inhibits fungal lanosterol 14α-demethylase (CYP51), disrupting ergosterol synthesis and causing fungal cell membrane damage.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Intravaginally, one suppository (100 mg miconazole nitrate) once daily at bedtime for 7 days or one suppository (200 mg) once daily for 3 days, combined with topical application of miconazole nitrate cream (2%) to the vulvar area twice daily for 7 days.
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life is approximately 20-25 hours, but can be prolonged to 30-40 hours in patients with hepatic impairment.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Primarily fecal (biliary) as unchanged drug and metabolites (~50-60%); renal excretion accounts for <20% of the dose, mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."